Checked, not settled
Checks out so far.
“In the 2026 HERBOT phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen had a 95% disease-control rate.”
2 of 4 review checks done · 1 counted · 1 by the author only
Supported · 0.8808 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited. The number is model-conditional, not a share of truth.
Share:
Checked in Galedra: score 0.88, mostly supported · not yet reviewed by anyone else
“In the 2026 HERBOT phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the trastuzumab-nivolumab-gemcitabine-cisplatin regimen had a 95%…”
https://galedra.org/claims/1d92841a-f7a3-8587-8777-d97b55e55a0b/card
Or just the link: https://galedra.org/claims/1d92841a-f7a3-8587-8777-d97b55e55a0b/card
See the evidence · 
Galedra